NCT00232063已完成3 期
Long-term Study of Ciclosporin for Atopic Dermatitis
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
In patients with severe adult atopic dermatitis, the safety and efficacy of OL27-400MEPC will be assessed by repeating oral administration at a dose of 3 mg/kg/day (2-5 mg/kg/day) in 2 divided doses daily for 8-12 weeks and recovery until 52 weeks after starting treatment
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •- Appropriate the definition/diagnosis criteria of atopic dermatitis of the Japanese Dermatological Association
- •Patients with severest atopic dermatitis [according to the "Guidelines for Treatment of Atopic Dermatitis 2002, the severity of atopic dermatitis will be classified as severest when an eruption associated with severe inflammation (a lesion associated with erythema, papule, erosion, infiltration, lichenification, etc.) is noted on at least 30% of body surface on the day of subject enrollment].
排除标准
- •Patients who received oral preparations, injections, inhaled preparations and suppositories of steroids or immunosuppressants other than tacrolimus hydrate ointments within 14 days of subject enrollment
- •Patients who might receive the oral/injection drugs which are known to enhance nephrotoxicity, increase serum potassium levels, HMG-CoA reductase inhibitors or theophylline during the treatment period.
- •Patients who received or are receiving an ultraviolet therapy (PUVA therapy, etc.)
- •Patients with hypertension, active infectional disease, gout etc. Other protocol-defined exclusion criteria may apply.
研究者
相似试验
已完成
3 期
Verification Study of Ciclosporin for Atopic DermatitisSevere Atopic DermatitisNCT00232076Novartis Pharmaceuticals
已完成
不适用
Photophoresis Versus Ciclosporine in Severe Atopic DermatitisAtopic DermatitisNCT02226068University of Aarhus20
招募中
1 期
Optimization of Cyclosporin therapy in atopic dermatitis through multiomic predictive models of treatment response (DermAtOmics)Adult, adolescent and paediatric patients with moderate-severe atopic dermatitisCTIS2022-500677-14-00Fundación Para La Investigación Biomédica Del Hospital Universitario La Paz100
招募中
4 期
Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment ResponseAtopic DermatitisNCT05692843Instituto de Investigación Hospital Universitario La Paz100
终止
4 期
Ciclosporin Versus Alitretinoin for Severe Atopic Hand Dermatitis.Atopic DermatitisNCT01231854Technische Universität Dresden15